A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma (Q33380865)

26 July 2017

title

A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma (English)

1 reference

26 July 2017

main subject

phase II clinical trial

0 references

1 reference

1 reference

0 references

1 reference

Ahmad A Tarhini

1 reference

26 July 2017

John M Kirkwood

1 reference

26 July 2017

William E Gooding

1 reference

26 July 2017

Stergios Moschos

1 reference

26 July 2017

Sanjiv S Agarwala

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 October 2008

1 reference

26 July 2017

1 reference

26 July 2017

volume

113

1 reference

26 July 2017

1 reference

26 July 2017

page(s)

1632-1640

1 reference

The current causes of death in patients with malignant melanoma

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23791

A randomized trial of surgery in the treatment of single metastases to the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23791

Gamma-Knife radiosurgery in the management of melanoma patients with brain metastases: a series of 106 patients without whole-brain radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23791

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23791

7 January 2021

Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23791

7 January 2021

Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Gr

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23791

7 January 2021

Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23791

7 January 2021

A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23791

7 January 2021

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23791

7 January 2021

Antitumor imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one , a novel broad-spectrum antitumor agent

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23791

7 January 2021

Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23791

7 January 2021

Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23791

7 January 2021

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23791

7 January 2021

Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23791

7 January 2021

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23791

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23791

7 January 2021

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23791

7 January 2021

Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23791

7 January 2021

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23791

7 January 2021

Clinical trial designs for cytostatic agents: are new approaches needed?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23791

7 January 2021

Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23791

7 January 2021

Metastatic pattern of malignant melanoma. A study of 216 autopsy cases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23791

7 January 2021

Central nervous system metastases in malignant melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23791

7 January 2021

Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23791

7 January 2021

Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23791

7 January 2021

Resection for solitary brain metastasis. Role of adjuvant radiation and prognostic variables in 229 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23791

7 January 2021

Long-term survivors after gamma knife radiosurgery for brain metastases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23791

7 January 2021

Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23791

7 January 2021

Identifiers

DOI

10.1002/CNCR.23791

1 reference

26 July 2017

1 reference